An Open-Label, Multi-Cetre, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients With Depression

Trial Profile

An Open-Label, Multi-Cetre, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients With Depression

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Bupropion (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Jan 2005 to Dec 2004 as reported by Clinicaltrials.gov.
    • 15 Nov 2007 Status changed from in progress to completed.
    • 02 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top